Screener
Organon OGN China — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
FAQ
- What is Organon's china — revenue?
- Organon (OGN) reported china — revenue of $194M in Q1 2026.
- How has Organon's china — revenue changed year-over-year?
- Organon's china — revenue decreased by 4.9% year-over-year, from $204M to $194M.
- What is the long-term trend for Organon's china — revenue?
- Over 4 years (2021 to 2025), Organon's china — revenue has grown at a -2.9% compound annual growth rate (CAGR), from $934M to $829M.
- What does china — revenue mean?
- This metric represents the total net sales generated from pharmaceutical products sold within the China geographic market. It reflects the company's commercial performance and market penetration in this specific region across its portfolio of women's health, biosimilars, and established brands. Monitoring this figure helps investors assess the company's regional growth trajectory and exposure to local healthcare policy and competitive dynamics.
Ask your AI about Organon's china — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude